Stock 600436 ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Zhangzhou Pientzehuang Pharmaceutical., Ltd

Equities

600436

CNE000001F21

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-07-02 pm EDT 		5-day change 1st Jan Change
205.1 CNY -0.85% Intraday chart for Zhangzhou Pientzehuang Pharmaceutical., Ltd -4.35% -15.26%
Jun. 21 Pientzehuang Pharmaceutical Gets Nod to Trails Lymphoma Drug MT
Apr. 19 Zhangzhou Pientzehuang Pharmaceutical., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 65,515 161,393 263,740 174,033 145,997 123,722 - -
Enterprise Value (EV) 1 61,949 156,943 257,442 172,616 145,897 120,211 118,730 115,944
P/E ratio 48.2 x 96.6 x 108 x 70.5 x 52.2 x 36.8 x 31.4 x 26.5 x
Yield 0.75% 0.34% 0.28% 0.43% 0.96% 1.19% 1.29% 1.43%
Capitalization / Revenue 11.4 x 24.8 x 32.9 x 20 x 14.5 x 10.7 x 9.41 x 8.31 x
EV / Revenue 10.8 x 24.1 x 32.1 x 19.9 x 14.5 x 10.4 x 9.03 x 7.79 x
EV / EBITDA 36.3 x 75.5 x 85.9 x 56.2 x 41.8 x 29.9 x 25.2 x 20.7 x
EV / FCF -66.5 x 138 x 686 x 25.8 x 70.6 x 35.2 x 30.8 x 25.7 x
FCF Yield -1.5% 0.72% 0.15% 3.88% 1.42% 2.84% 3.24% 3.89%
Price to Book 10 x 20.5 x 27.2 x 15.4 x 10.9 x 7.98 x 6.8 x 5.78 x
Nbr of stocks (in thousands) 596,297 603,317 603,317 603,317 603,317 603,317 - -
Reference price 2 109.9 267.5 437.2 288.5 242.0 205.1 205.1 205.1
Announcement Date 1/17/20 1/19/21 1/19/22 1/30/23 4/19/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 5,722 6,511 8,022 8,692 10,058 11,524 13,151 14,887
EBITDA 1 1,705 2,080 2,997 3,071 3,488 4,024 4,712 5,602
EBIT 1 1,638 1,977 2,874 2,956 3,394 3,988 4,666 5,532
Operating Margin 28.63% 30.37% 35.83% 34.01% 33.74% 34.61% 35.48% 37.16%
Earnings before Tax (EBT) 1 1,645 1,979 2,869 2,958 3,369 4,039 4,742 5,594
Net income 1 1,374 1,672 2,431 2,469 2,797 3,358 3,939 4,659
Net margin 24.02% 25.67% 30.31% 28.4% 27.81% 29.14% 29.95% 31.3%
EPS 2 2.280 2.770 4.030 4.090 4.640 5.568 6.529 7.726
Free Cash Flow 1 -931.6 1,134 375.4 6,698 2,066 3,418 3,850 4,506
FCF margin -16.28% 17.42% 4.68% 77.05% 20.54% 29.66% 29.28% 30.27%
FCF Conversion (EBITDA) - 54.54% 12.53% 218.06% 59.24% 84.92% 81.72% 80.44%
FCF Conversion (Net income) - 67.86% 15.44% 271.27% 73.86% 101.79% 97.76% 96.71%
Dividend per Share 2 0.8200 0.9000 1.210 1.250 2.320 2.450 2.640 2.937
Announcement Date 1/17/20 1/19/21 1/19/22 1/30/23 4/19/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 - - - - 2,077 2,630 2,416 2,555 2,459 3,171 3,116 3,022 2,781 3,769 -
EBITDA - - - - - - - - - - - - - - -
EBIT 1 - - - - 469.5 939.6 915.1 1,037 494.6 1,171 1,103 1,209 672.3 1,347 -
Operating Margin - - - - 22.61% 35.73% 37.88% 40.58% 20.12% 36.94% 35.41% 40.01% 24.18% 35.75% -
Earnings before Tax (EBT) - - - - - - - - - - - - - - -
Net income - 689.3 - - - - - - - 974.5 - - - - -
Net margin - - - - - - - - - 30.73% - - - - -
EPS 2 0.7000 1.140 1.040 1.220 0.6900 1.280 1.260 1.440 0.6500 1.620 1.530 1.655 0.8550 1.955 1.820
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 1/19/22 4/22/22 7/18/22 10/21/22 1/30/23 4/14/23 7/13/23 10/16/23 4/19/24 4/19/24 - - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 3,567 4,450 6,298 1,417 99.6 3,512 4,992 7,779
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -932 1,134 375 6,698 2,066 3,418 3,851 4,506
ROE (net income / shareholders' equity) 23.6% 23.1% 27.7% 23.5% 22.6% 22.1% 22.1% 21.7%
ROA (Net income/ Total Assets) 17.8% 17.6% 21.4% 18.3% 17.7% 17.8% 18.8% 19.3%
Assets 1 7,734 9,508 11,382 13,458 15,842 18,827 20,896 24,162
Book Value Per Share 2 11.00 13.00 16.10 18.80 22.20 25.70 30.20 35.50
Cash Flow per Share 2 -1.460 2.430 0.7700 11.40 3.660 5.450 5.590 7.360
Capex 1 52.3 333 86.9 175 141 101 198 232
Capex / Sales 0.91% 5.11% 1.08% 2.02% 1.4% 0.88% 1.51% 1.56%
Announcement Date 1/17/20 1/19/21 1/19/22 1/30/23 4/19/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Zhangzhou Pientzehuang Pharmaceutical., Ltd

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
205.1 CNY
Average target price
285.8 CNY
Spread / Average Target
+39.35%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD Stock Zhangzhou Pientzehuang Pharmaceutical., Ltd
-15.26% 17.02B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+54.07% 809B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+38.59% 621B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.05% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.44% 319B
ABBVIE INC. Stock AbbVie Inc.
+5.72% 289B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.40% 238B
ROCHE HOLDING AG Stock Roche Holding AG
+0.61% 221B
NOVARTIS AG Stock Novartis AG
+13.24% 218B
AMGEN INC. Stock Amgen Inc.
+7.42% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 600436 Stock
  4. Financials Zhangzhou Pientzehuang Pharmaceutical., Ltd